Drug Guidance for Subsidy 01/04/2020 Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for treating benign prostatic hyperplasia The Ministry of Health’s Drug Advisory Committee has recommended: Alfuzosin 10 mg tablet and... See all × 01/04/2020 Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for treating benign prostatic hyperplasia The Ministry of Health’s Drug Advisory Committee has recommended: Alfuzosin 10 mg tablet and dutasteride 0.5 mg capsule for treating benign prostatic hyperplasia Subsidy status RAlfuzosin 10 mg tablet and dutasteride 0.5 mg capsule are recommended for inclusion on the MOH Standard Drug List (SDL). NRSDL subsidy does not apply to tamsulosin 0.4 mg tablet or dutasteride 0.5 mg/tamsulosin 0.4 mg capsule.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet 10 mg Alexandra Hospital Changi General Hospital Institute of Mental Health Khoo Teck Puat Hospital National Cancer Centre National Healthcare Group Polyclinics Ng Teng Fong General Hospital National University Hospital National University Polyclinics Sengkang General Hospital Singapore General Hospital SingHealth Polyclinics Tan Tock Seng Hospital Woodlands Health Campus
ORAL Select a brand starting with the letter: A R X APO-ALFUZOSIN PROLONGED RELEASE TABLET 10MG [SIN15512P] RANFUZOSIN MODIFIED RELEASE TABLETS 10MG [SIN13984P] XATRAL SR TABLET 5 MG [SIN09546P] XATRAL XL TABLET 10 MG [SIN11579P]